Dr Pierre Martin-Hirsch

Consultant Gynaecological Oncologist and Gynaecologist Job title: Consultant Gynaecological Oncologist and Gynaecologist

Department: Obstetrics and Gynaecology

Telephone number: 01772 524442

Primary medical qualification: MBCHB

Other qualifications: BSFROG MD

Year of registration: 1987

GMC number: 420391

Career history:

Specialist training in obstetrics and gynaecology, NW Deanery .
Wellbeing Research Fellow, St James's University Hospital, Leeds
RCOG Subspecialty Trainee/ Lecturer in Gynaecological Oncology, Manchester University / Christie / St Mary’s Hospital .
Consultant Gynaecological Oncologist and Gynaecologist for Lancashire Teaching Hospitals NHS Foundation Trust (2001-present),

Trust Lead for Gynaecological Oncology

Hon Professor Lancaster University , Hon SL UCLAN,  Editor BJOG & Secretary of British Colposcopy Society, Executive Board of International Federation of Colposcopy , North West Coastal research network lead for Reproductive Health and Gynaecological Oncology

Specialist areas: Gynaecological oncology; colposcopy; vulval / vaginal precancer; oncology training

Specialist Interests: Minimal access surgery,  Vulval disorders , colposcopy, ovarian cancer surgery, patient information

Research interests: Evidence Based Practice  in Gynaecological oncology, Imaging, Surgery in ovarian Cancer, Follow-up care, Patient information, Translational research, outcomes after treatment of cervical pre-cancer. >100 published papers. Supervision of academic trainees, clinical research fellows undertaking MDs, PHD students.

Clinics: Gynaecological Oncology Clinic; Colposcopy Clinic; Vulva CLinic; Gynaecology Clinic

Improving Outcomes in Gynaecological Oncology;
H.C. Kitchener, P.L. Martin-Hirsch 1997 NHS Executive

Pilot Study of Photodynamic Therapy For VIN / CIN
P.L. Martin-Hirsch, HC. Kitchener 1997 Central Manchester R+D

Supra-regional Audit of Maternity Care for Pregnant Adolescents
M.W. Seif, P.L. Martin-Hirsch, M. Maresh 1998 North West R+D
R.C.T. evaluating strategies to improve compliance for colposcopyA. Tomlinson, P.L. Martin-Hirsch 1998

Central Manchester R+D
R.C.T evaluating a novel collection device for cervical cytology
P.L. Martin-Hirsch, H. Kitchener 2000   Ampersand International

Cochrane / Systematic Reviews in Cervical Screening
P.L. Martin-Hirsch., M. Arbyn  2005   Cochrane Collaboration   
Characterisation of cervical cells employing photothermal micro-spectroscopy +
Characterisation of DNA adducts in endometrium  2005+2006 
P.L. Martin-Hirsch, F. Martin .LTHT and Rosemere Cancer Charity
Synucleins as Biomarkers and Potential Targets for Intervention in Cancer Progression
Dr. O El-Agnaf, P.Martin-Hirsch, S Aswad, F Martin  2005
Terry Fox Fund for Cancer Research
Human Ovarian Cancer: Stem Cells & Drug Resistance 2006

Professor Hassan T Hassan, P.L. Martin-Hirsch
NHS Cochrane Collaboration Programme Grant Scheme
Diagnosis and treatment of gynaecological cancer: improving the evidence for the NHS 2007

Khalid Khan, Sudha Sundhar, Pierre Martin-Hirsch, Trcey Roberts, Peter Guest Clinical Effectiveness of PET-CT imaging in restaging cervical cancer: systematic review and economic modelling:  HTA  June 2010

Andrea Rockall, Jon Hill, Pierre Martin-Hirsch, Sundha Sudhar, Richard Edmunson and Colleagues Prospective study evaluating PET in diagnosing lymph node disease in uterine and cervical cancer: Preston / Barts / Cambridge / Birmingham CRUK funded Nov 2010

C. Williams, P. Martin-Hirsch, R. Naik, J. Morrison S. Kehoe  Optimising care, diagnosis and treatment pathways to ensure cost effectiveness and best practice in gynaecological cancer: improving the evidence for the NHS: NIHR Cochrane Collaboration Programme Grant Scheme Jan 2011
K. Beaver, P. Martin-Hirsch  A.Tomlinson, S Williamson, C. Sutton Comparing hospital and telephone follow-up for women treated for endometrial cancer (ENDOCAT: Endometrial Cancer telephone follow-up trial. RFPB April 2011
Towards disease diagnosis through spectrochemical imaging of tissue architecture.

Engineering and Physics Research Council April 2013 :  Weightman and colleagues.

Liverpool / Lancaster Universities I am a clinical partner with Lancashire  Teaching Hospitals as the healthcare partner
Development of multimedia patient information resources for all cancers; Rosemere Cancer Charity 2014


Back to the list

New state-of-the-art cancer robot arrives

New state-of-the-art cancer robot arrives

We have taken delivery of a new state-of-the-art robot that will improve outcomes for patients with cancer.

Our Regional Specialised Cancer Centre is the first hospital in the north of England to have the latest advanced robotic surgical system, which will treat patients from Lancashire and South Cumbria who have bowel, gastrointestinal, urological and gynaecological cancers.  The centre is also just one of three in the country, and the only one in the North West, to be able to provide treatment for upper gastrointestinal cancer using this new robot. 

The robot can bend and rotate 360 degrees, making it much easier for our surgeons to access parts of the body that are difficult to reach, and undertake complex procedures using keyhole incisions rather than open surgery, reducing the risk of complications and enabling a speedier recovery.

Our cancer surgeons will now undertake five weeks of bespoke training before visiting world renowned centres in Europe to complete their learning and practise skills.

Pierre Martin-Hirsch, one of our Consultant Gynaecological Oncologists, said: “The whole team at the Regional Specialised Cancer Centre is excited by the arrival of the new robot, and are looking forward to completing our training so we can offer the very latest treatment to our patients. This new version of the robot will put us at the top of the league for cervical cancer treatment as well as many other cancers.”

Mark Pugh, our Medical Director, said: “We are delighted to be the first hospital in the north of England to secure the latest in robotic technology, and we are proud to be leading the way in cancer treatment. This new equipment will help us to continue to provide the very best care for our patients and we thank the Rosemere Cancer Foundation for their support in helping us to do that.”

Rosemere Cancer Foundation has launched a fundraising campaign to pay for the robot, which has been delivered to our Regional Specialised Cancer Centre, so that the latest cancer treatment can be offered to patients immediately. 

In future, the centre will aim to become the European training hub for the advancement of robotic surgery.

If you would like to make a donation to the Rosemere Cancer Foundation’s 20th anniversary appeal which is raising funds to pay for the robot, visit www.rosemere.org.uk.